Arcadia Biosciences, Inc.
RKDA
$0.92
-$0.11-10.85%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -9.53% | -3.73% | 12.29% | 23.81% | 20.65% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -9.53% | -3.73% | 12.29% | 23.81% | 20.65% |
| Cost of Revenue | 1.92% | 8.60% | 40.16% | 64.91% | 52.66% |
| Gross Profit | -25.55% | -19.87% | -13.22% | -10.11% | -6.72% |
| SG&A Expenses | -30.89% | -27.41% | -6.79% | 5.52% | 21.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.76% | -19.17% | 2.68% | 16.90% | 27.64% |
| Operating Income | 32.53% | 29.62% | 4.37% | -11.80% | -33.35% |
| Income Before Tax | -1,122.44% | 45.89% | -595.03% | -3,806.08% | -167.73% |
| Income Tax Expenses | 0.00% | 0.00% | 14.29% | 14.29% | 0.00% |
| Earnings from Continuing Operations | -1,110.78% | 45.81% | -589.47% | -3,664.89% | -168.93% |
| Earnings from Discontinued Operations | -- | -- | 99.47% | 93.07% | 84.70% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -362.45% | 66.77% | 13.04% | -11.10% | 71.28% |
| EBIT | 32.53% | 29.62% | 4.37% | -11.80% | -33.35% |
| EBITDA | 32.20% | 28.98% | 2.83% | -15.42% | -38.89% |
| EPS Basic | -286.53% | 66.94% | 13.28% | -10.71% | 71.33% |
| Normalized Basic EPS | -22.30% | 37.62% | -71.59% | -147.65% | -544.28% |
| EPS Diluted | -196.99% | 69.38% | 21.40% | -1.66% | 62.63% |
| Normalized Diluted EPS | -1.31% | 63.94% | -56.91% | -164.92% | -458.40% |
| Average Basic Shares Outstanding | 13.40% | 0.35% | 0.28% | 0.30% | 0.30% |
| Average Diluted Shares Outstanding | 2.11% | -7.68% | -7.74% | -7.79% | 33.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |